Cargando…

Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect

This manuscript investigates cabozantinib, vandetanib, pralsetinib, and selpercatinib, four tyrosine kinase inhibitors (TKIs), which are used to treat advanced and/or metastatic medullary thyroid cancer (MTC). Data on efficacy and safety are presented with the main focus on treatment-related hyperte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Højer Wang, Linnea, Wehland, Markus, Wise, Petra M., Infanger, Manfred, Grimm, Daniela, Kreissl, Michael C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917177/ https://www.ncbi.nlm.nih.gov/pubmed/36768635 http://dx.doi.org/10.3390/ijms24032312

Ejemplares similares

Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension
por: Milling, Rikke Vilsbøll, et al.
Publicado: (2018)

Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model
por: Carra, Silvia, et al.
Publicado: (2021)

Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies
por: Grande, Enrique, et al.
Publicado: (2013)

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations
por: Subbiah, V., et al.
Publicado: (2020)

The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib
por: Shen, Tao, et al.
Publicado: (2021)

Salvage Therapy With Selpercatinib for RET-Rearranged NSCLC With Pralsetinib-Related Pneumonitis and Leptomeningeal Disease: A Case Report
por: d'Arienzo, Paolo D., et al.
Publicado: (2023)

Neoadjuvant selpercatinib for advanced medullary thyroid cancer
por: Jozaghi, Yelda, et al.
Publicado: (2020)

Kinase-Inhibitors in Iodine-Refractory Differentiated Thyroid Cancer—Focus on Occurrence, Mechanisms, and Management of Treatment-Related Hypertension
por: Kaae, Anne Christine, et al.
Publicado: (2021)

Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer
por: Degrauwe, Nils, et al.
Publicado: (2012)

Role of vandetanib in the management of medullary thyroid cancer
por: Brassard, Maryse, et al.
Publicado: (2012)

Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer
por: Deshpande, Hari, et al.
Publicado: (2011)

Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial
por: Kreissl, Michael C., et al.
Publicado: (2020)

Successful Treatment with Selpercatinib for Ectopic Cushing’s Syndrome Due to Medullary Thyroid Cancer
por: Ragnarsson, Oskar, et al.
Publicado: (2022)

The Adverse Effect of Hypertension in the Treatment of Thyroid Cancer with Multi-Kinase Inhibitors
por: Ancker, Ole Vincent, et al.
Publicado: (2017)

Cabozantinib for the Treatment of Metastatic Medullary Thyroid Carcinoma
por: Nix, Nancy M., et al.
Publicado: (2014)

Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer
por: Deshpande, Hari, et al.
Publicado: (2011)

Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes
por: Fallahi, Poupak, et al.
Publicado: (2019)

Ectopic Cushing’s Syndrome and Severe Hypocalcemia Due to Medullary Thyroid Cancer Responsive to Selpercatinib
por: Turin, Christie Gloria, et al.
Publicado: (2021)

Rapid and long-lasting response to selpercatinib of paraneoplastic Cushing’s syndrome in medullary thyroid carcinoma
por: Sitbon, Marine, et al.
Publicado: (2022)

Significant response to pralsetinib in a medullary thyroid cancer harboring double RET variants of unknown significance
por: Hescot, Ségolène, et al.
Publicado: (2022)

Unusual increase in carcinoembryonic antigen despite response to selpercatinib in two patients with medullary thyroid cancer
por: Bardet, Stéphane, et al.
Publicado: (2022)

Volumetric and texture analysis of pretherapeutic (18)F-FDG PET can predict overall survival in medullary thyroid cancer patients treated with Vandetanib
por: Werner, Rudolf A., et al.
Publicado: (2018)

Vandetanib
por: Vozniak, J. Michael, et al.
Publicado: (2012)

Patterns of thyroid hormone levels in pediatric medullary thyroid carcinoma patients on vandetanib therapy
por: Lodish, Maya, et al.
Publicado: (2015)

Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience
por: Kim, Mijin, et al.
Publicado: (2020)

Phototoxic drug eruption induced by vandetanib used for the treatment of metastatic medullary thyroid cancer()
por: Bostan, Ecem, et al.
Publicado: (2022)

Cabozantinib for progressive metastatic medullary thyroid cancer: a review
por: Colombo, Joshua R, et al.
Publicado: (2014)

Selpercatinib: First Approval
por: Markham, Anthony
Publicado: (2020)

Prolonged Exposure to Simulated Microgravity Changes Release of Small Extracellular Vesicle in Breast Cancer Cells
por: Wise, Petra M., et al.
Publicado: (2022)

Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment
por: Werner, R.A., et al.
Publicado: (2015)

Effect of Vandetanib Treatment on Cystic Changes in the Liver following Metastasis from Medullary Thyroid Carcinoma
por: Matsui, Ai, et al.
Publicado: (2022)

The Effect of Continuous Positive Airway Pressure Therapy on Obstructive Sleep Apnea-Related Hypertension
por: Baran, Ronni, et al.
Publicado: (2021)

Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer
por: Hart, Christopher D, et al.
Publicado: (2013)

Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature
por: Kapur, Sakshi, et al.
Publicado: (2014)

Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma
por: Bendtsen, Mathias Alrø Fichtner, et al.
Publicado: (2017)

Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma
por: Schlumberger, M, et al.
Publicado: (2017)

Correction to: Selpercatinib: First Approval
por: Markham, Anthony
Publicado: (2020)

Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment: Erratum
Publicado: (2016)

Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer
por: Del Rivero, Jaydira, et al.
Publicado: (2018)

Changes in Exosome Release in Thyroid Cancer Cells after Prolonged Exposure to Real Microgravity in Space
por: Wise, Petra M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d5lng0s72v0p96rn376vbko5dt